Could arthritis drug humira ease rare skin disease?
NCT ID NCT02113904
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested whether Humira (adalimumab), a drug used for arthritis, can help people with Netherton syndrome, a rare genetic skin condition that causes severe inflammation, itching, and pain. Eleven patients received six injections over three months, followed by three months of monitoring. The goal was to see if the drug could reduce skin symptoms by at least 20% and improve quality of life, while watching for risks like infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Humira (adalimumab)
- What this could lead to
- If it works, this could point toward a treatment that reduces skin inflammation and improves quality of life for people with Netherton syndrome.
- What could go wrong
- This is a small, early-phase trial with only 11 people, so results may not apply to everyone. Humira also carries risks like serious infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Necker Enfants Malades hospital
Paris, Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New lotion shows promise for rare skin disorder
- Experimental drug for rare skin disease fails to reach goal
- Scientists hunt for clues to ichthyosis in skin and blood
- Microbiome study seeks clues in rare skin condition
- New cream shows promise for rare skin condition
- Rare skin disease mystery unraveled: new study maps netherton Syndrome's inner workings